HCA
MLTX icon

Harbor Capital Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Harbor Capital Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,706
Closed -$98K – 1359
2025
Q3 		$98K Sell
13,706
-37,703
-73% -$1.97M 0.01% 662
2025
Q2 		$2.43M Sell
51,409
-50,611
-50% -$2.06M 0.1% 256
2025
Q1 		$3.99M Buy
102,020
+22,372
+28% +$964K 0.18% 177
2024
Q4 		$4.31M Buy
79,648
+2,180
+3% +$111K 0.19% 162
2024
Q3 		$3.91M Buy
77,468
+38,779
+100% +$1.82M 0.17% 175
2024
Q2 		$1.7M Buy
38,689
+30,481
+371% +$1.29M 0.13% 237
2024
Q1 		$412K Buy
+8,208
New +$445K 0.05% 447

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Harbor Capital Advisors's MLTX Position: Q4 2025 in Review

Harbor Capital Advisors sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 13,706 shares — an estimated $98K sold.

Harbor Capital Advisors first reported a position in MLTX in Q1 2024 and held it in 7 quarters. The position peaked at $4.31M in Q4 2024. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

  • Harbor Capital Advisors reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Harbor Capital Advisors sold 13,706 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $98K.
  • Harbor Capital Advisors first reported a position in MoonLake Immunotherapeutics in Q1 2024 and held it in 7 quarters.
  • Harbor Capital Advisors's MoonLake Immunotherapeutics position peaked at $4.31M in Q4 2024.
  • 130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Harbor Capital Advisors's 13F filing for Q4 2025, filed 20 Jan 2026.